Products
Modakafusp Biosimilar Antibody Fusion Protein (CD38) for Research
Cat No.: GMP-Bios-ab-352
Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Modakafusp alfa (formerly TAK 573 or TEV 48573) is a CD38 targeted antibody (IgG4) fused with attenuated interferon alpha (IFN-α), being developed by Takeda, through its wholly-owned subsidiary Millennium Pharmaceuticals, for the treatment of multiple myeloma and solid tumours.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-352-1mg | 1mg | |
| GMP-Bios-ab-352-10mg | 10mg | |
| GMP-Bios-ab-352-100mg | 100mg | |
| GMP-Bios-ab-352-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody |
| INN Name | Modakafusp |
| Target | ADPRC |
| Format | Whole mAb Fusion |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Takeda |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Development Tech | na |
